Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis to acquire Corthera and relaxin rights

Novartis to acquire Corthera and relaxin rights

24th December 2009

Novartis revealed this week that it plans to acquire Corthera ? a move that will result in the company also gaining the rights to the drug relaxin.

Relaxin has previously been shown to possess vasodilator abilities, which improves breathlessness reduces cardiovascular morbidity and the number of days an individual needs to spend in hospital.

As part of the agreement, Novartis will pay US$120 million (74.9 million pounds) for Corthera, with the latter firm’s shareholders being eligible for additional payments of up to $500 million with the advent of various milestones.

Trevor Mundel, global head of development at Novartis, commented: “Relaxin will be an important addition to our expanding pipeline of novel development projects targeting cardiovascular disease.”

Earlier this month, Novartis revealed that a phase III trial demonstrated the effectiveness of its product Tasigna (nilotinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.